ARTICLE | Clinical News
LJPC reports additional LJP 394 data
February 16, 2000 8:00 AM UTC
La Jolla Pharmaceutical (LJPC) presented additional data from a Phase II/III study of its LJP 394 carrier plus epitope that binds to double-stranded DNA (dsDNA) antibodies on B cells to treat lupus ne...